keyword
https://read.qxmd.com/read/38634917/pharmacogenetic-guided-versus-standard-warfarin-dosing-for-routine-clinical-care-with-its-pharmacoeconomic-impact-a-randomized-controlled-clinical-trial
#21
JOURNAL ARTICLE
Aishwarya Anand, Naveen C Hegde, Pulkit Chhabra, Jai Purohit, Rupesh Kumar, Ankur Gupta, Deepesh P Lad, Ritin Mohindra, Saurabh Mehrotra, Rajesh Vijayvergiya, Basant Kumar, Vishal Sharma, Pankaj Malhotra, Jasmina Ahluwalia, Reena Das, Amol N Patil, Nusrat Shafiq, Samir Malhotra
BACKGROUND: Empirical use of pharmacogenetic test(PGT) is advocated for many drugs, and resource-rich setting hospitals are using the same commonly. The clinical translation of pharmacogenetic tests in terms of cost and clinical utility is yet to be examined in hospitals of low middle income countries (LMICs). AIM: The present study assessed the clinical utility of PGT by comparing the pharmacogenetically(PGT) guided- versus standard of care(SOC)- warfarin therapy, including the health economics of the two warfarin therapies...
April 18, 2024: Annals of Hematology
https://read.qxmd.com/read/38634916/covid-19-severity-in-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-a-single-center-observational-cohort-study
#22
JOURNAL ARTICLE
Sophie Thau, Christian Bjørn Poulsen, Christian Brieghel, Morten Kranker Larsen, Lothar Wiese, Xiaohui Chen Nielsen, Lars Møller Pedersen
Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023...
April 18, 2024: Annals of Hematology
https://read.qxmd.com/read/38634915/incidence-of-pleural-effusion-with-dasatinib-and-the-effect-of-switching-therapy-to-a-different-tki-in-patients-with-chronic-phase-cml
#23
JOURNAL ARTICLE
Akriti G Jain, Quinto Gesiotto, Somedeb Ball, Lisa Nodzon, Amanda Rodriguez, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David A Sallman, Jeffrey E Lancet, Javier Pinilla-Ibarz, Kendra Sweet
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch. A total of 390 patients were treated with dasatinib during their course of treatment for CP-CML...
April 18, 2024: Annals of Hematology
https://read.qxmd.com/read/38634914/immune-reconstitution-after-single-unit-umbilical-cord-blood-transplantation-using-anti-thymoglobulin-and-myeloablative-conditioning-in-adults-with-hematological-malignancies
#24
JOURNAL ARTICLE
Lourdes Cordón, Pedro Chorão, Beatriz Martín-Herreros, Juan Montoro, Aitana Balaguer, Manuel Guerreiro, Marta Villalba, Ana Facal, Pedro Asensi, Pilar Solves, Inés Gómez, Marta Santiago, Brais Lamas, Ana Bataller, Pablo Granados, Amparo Sempere, Guillermo F Sanz, Miguel A Sanz, Jaime Sanz
This study aimed to investigate the kinetics of immune recovery following umbilical cord blood transplantation (UCBT) in adults who received a myeloablative conditioning (MAC) regimen and antithymocyte globulin (ATG). While the immune recovery kinetics has been extensively studied in pediatric UCBT recipients, limited data exist for adults. We conducted a comprehensive analysis of 221 consecutive adult patients who underwent UCBT with MAC and ATG at a single institution. Our objective was to evaluate the influence of patient, disease, and transplant factors, along with acute graft-versus-host disease (aGVHD), on immune reconstitution and overall survival...
April 18, 2024: Annals of Hematology
https://read.qxmd.com/read/38634910/40%C3%A2-years-neonatology-an-academic-life
#25
REVIEW
Arnold Pollak
BACKGROUND: A complete review of the development of neonatology in the last 40 years would probably require a compendium with several volumes, to bring to view the remarkable improvements in survival rates and neurodevelopmental outcomes of ill babies in Austria, most industrial countries and to some extent worldwide. The challenge I had to solve here was to integrate my own contributions to the field of neonatology during this period and particularly the contributions of my team from the Division of Neonatology and Pediatric Intensive Care Medicine, Department of Pediatrics and Adolescence Medicine, Medical University Vienna where I was working first as an intern and resident and later had the privilege to become head of department...
April 18, 2024: Wiener Klinische Wochenschrift
https://read.qxmd.com/read/38634725/sickle-cell-health-awareness-perspectives-and-experiences-shape-survey-perspectives-of-adolescent-and-adult-patients-caregivers-and-healthcare-professionals-on-the-burden-of-sickle-cell-disease
#26
JOURNAL ARTICLE
Mariane de Montalembert, Alan Anderson, Fernando F Costa, Baba P D Inusa, Wasil Jastaniah, Joachim B Kunz, Biba Tinga, Elvie Ingoli, John James, Regina Hartfield, Anne Beaubrun, Belinda Lartey, Isaac Odame
OBJECTIVES: Sickle cell disease (SCD) is an inherited disorder that causes lifelong complications, substantially impacting the physical and emotional well-being of patients and their caregivers. Studies investigating the effects of SCD on quality of life (QOL) are often limited to individual countries, lack SCD-specific QOL questionnaires, and exclude the caregiver experience. The SHAPE survey aimed to broaden the understanding of the global burden of SCD on patients and their caregivers and to capture the viewpoint of healthcare providers (HCPs)...
April 18, 2024: European Journal of Haematology
https://read.qxmd.com/read/38634345/anti-d-immunization-after-d-positive-platelet-transfusions-in-d-negative-recipients-a-systematic-review-and-meta-analysis
#27
REVIEW
Tamar Hubert, Jean Louis Kerkhoffs, Anneke Brand, Henk Schonewille
BACKGROUND: Anti-D can be formed after D-incompatible platelet transfusions due to contaminating D+ red blood cells. These antibodies are of particular importance in women of childbearing potential, because anti-D is most often involved in severe cases of hemolytic disease of the fetus and newborn. This systematic review determined the frequency of anti-D after D+ platelet transfusions and risk factors for D alloimmunization. STUDY DESIGN AND METHODS: Relevant literature was searched using PubMed, Embase and Web of Science until December 2022...
April 18, 2024: Transfusion
https://read.qxmd.com/read/38634344/neutrophil-antigen-antibodies-affect-engraftment-and-secondary-graft-failure-in-hematopoietic-progenitor-cell-transplantation
#28
JOURNAL ARTICLE
Abdullah Alswied, Sajjad Hassan, Herleen Rai, Willy Albert Flegel
BACKGROUND: Research is limited on the role of antibodies against human neutrophil antigen (HNA) in hematopoietic progenitor cell (HPC) transplantation outcomes. STUDY DESIGN AND METHODS: A retrospective review was conducted on medical records of patients at the NIH Clinical Center enrolled in six research protocols. This case-control study included 21 patients tested for HNA antibodies from January 2010 to March 2022 who underwent HPC transplantation. In addition, 42 patients following the same research protocols were randomly selected as a control group...
April 18, 2024: Transfusion
https://read.qxmd.com/read/38634321/solitary-bone-plasmacytoma-of-the-skull-base-with-an-unusual-presentation
#29
JOURNAL ARTICLE
Tien-Ru Huang, Chun-Shu Lin, Hsin-Chien Chen
Solitary bone plasmacytoma (SBP) is a rare hematological malignancy that usually occurs in the spine and rarely in the skull. It rarely presents in the skull base, but presenting symptoms are associated with cranial nerve involvement depending on the site of the disease. We present the case of a 61-year-old man with an unusual presentation of hoarseness secondary to vocal fold palsy. Imaging showed a large bony lesion in the temporo-occipital region with involvement of the jugular foramen. Further detailed diagnostic procedures confirmed SBP of the skull base...
April 18, 2024: Ear, Nose, & Throat Journal
https://read.qxmd.com/read/38634256/analysis-of-ventricular-arrhythmias-and-sudden-death-from-prospective-randomized-clinical-trials-of-acalabrutinib
#30
JOURNAL ARTICLE
Jeff P Sharman, Paolo Ghia, Paulo Miranda, Naghmana Bajwa, Simon Rule, Bob Shaw, John F Seymour
This analysis investigated the incidence of sudden deaths (SDs) and non-fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient-years). Sixteen (1.2%) patients experienced SD or VA (event rate, 0.350/100 patient-years). Non-fatal VAs occurred in 11 (0.8%) patients, nine (0.7%) of whom had premature ventricular contractions only. SD and fatal VAs occurred in five (0.4%) patients (event rate, 0.109/100 patient-years; median time to event: 46...
April 17, 2024: British Journal of Haematology
https://read.qxmd.com/read/38634174/estimating-the-serological-underrecognition-of-patients-with-weak-or-partial-rhd-variants
#31
JOURNAL ARTICLE
Glenn Ramsey, Christina M Barriteau
BACKGROUND: For patients with weak or discrepant RhD RBC phenotypes, RHD genotyping is employed to determine need for RhD-negative management. However, many RHD variants are type D-negative or D-positive. Serological recognition rates (RRs) of weak and partial RHD variants are poorly characterized. STUDY DESIGN AND METHODS: Four US studies employing RHD genotyping for weak or discrepant RhD phenotypes provided data for race/ethnicity-specific serological recognition...
April 18, 2024: Transfusion
https://read.qxmd.com/read/38634145/not-all-central-nervous-system-lymphomas-are-created-equal
#32
JOURNAL ARTICLE
Alvaro J Alencar, Juan Pablo Alderuccio
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634143/hypomethylating-agents-are-associated-with-high-rates-of-hematologic-toxicity-in-patients-with-secondary-myeloid-neoplasms-developing-after-acquired-aplastic-anemia
#33
JOURNAL ARTICLE
Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander E Perl, David L Porter, Arlene Zeringue, Joseph H Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634141/outcome-of-infants-with-acute-lymphoblastic-leukemia-treated-with-the-chinese-children-s-cancer-group-acute-lymphoblastic-leukemia-2015-study-protocol
#34
JOURNAL ARTICLE
Alex Wk Leung, Jiaoyang Cai, Zhi Wan, Jiefen Qin, Yongjun Fang, Lirong Sun, Jiashi Zhu, Shaoyan Hu, Ningling Wang, Pan Gao, Xin Tian, Xiaofan Zhu, Fen Zhou, Xuedong Wu, Xiuli Ju, Xiaowen Zhai, Hua Jiang, Qun Hu, Changda Liang, Liangchun Yang, Hui Zhang, Jingyan Tang, Ju Gao, Ching-Hon Pui, Chi-Kong Li
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634128/-one-way-or-another-i-m-gonna-find-ya-mir-221-3p-finds-its-targets-via-small-extracellular-vesicles
#35
JOURNAL ARTICLE
Jonathan Tak-Sum Chow, Leonardo Salmena
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634127/beyond-adenosine-triphosphate-unveiling-the-pleiotropic-effects-of-pyruvate-kinase-activation-in-sickle-cell-anemia
#36
JOURNAL ARTICLE
https://read.qxmd.com/read/38634126/validation-of-mutated-cebpa-bzip-as-a-distinct-prognosis-entity-in-acute-myeloid-leukemia-a-study-by-the-spanish-pethema-registry
#37
JOURNAL ARTICLE
Esther Prados De la Torre, Josefina Serrano, David Martínez-Cuadrón, Laura Torres, Claudia Sargas, Rosa Ayala, Cristina Bilbao-Sieyro, María Carmen Chillón, María José Larráyoz, Elena Soria, Clara Aparicio-Pérez, Juan M Bergua, Teresa Bernal, Cristina Gil, Mar Tormo, Lorenzo Algarra, Juan M Alonso-Domínguez, Eduardo Rodriguez-Arbolí, Pilar Martínez-Sanchez, Ana Oliva, Ana M Colorado-Araujo, Carlos Rodríguez-Medina, Susana Vives, Lourdes Hermosín, Joaquín Martínez-López, Ramón García-Sanz, José A Pérez-Simón, María José Calasanz, María Teresa Gómez-Casares, Eva Barragán, Joaquín Sánchez-García J, Pau Montesinos
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634121/-irf4-bloc1s5-the-first-rearrangement-gene-identified-in-tempi-syndrome
#38
JOURNAL ARTICLE
Ming Zhao, Jia Liu, Qing Yu, Wenbin Xu, Zilu Zhang, Ze Fu, Mingyuan Jia, Xinyi Zeng, Chengyu Wu, Chenjing Ye, Chao Wu, Yingli Wu, Ruibao Ren, Junmin Li, Kankan Wang, Hua Yan
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634119/-tp3-binding-domain-mutations-are-bad-news-in-burkitt-lymphoma
#39
JOURNAL ARTICLE
Mitchell S Cairo
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38633898/improved-survival-outcomes-with-anakinra-over-etoposide-based-therapies-for-the-management-of-adults-with-hemophagocytic-lymphohistiocytosis-a-retrospective-multicenter-research-network-study
#40
JOURNAL ARTICLE
Benjamin J Lee
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening, hyperinflammatory syndrome for which etoposide-based regimens have historically been the standard of care. Recent reports have described positive outcomes with the utilization of ruxolitinib or anakinra although these studies are often limited to small samples. OBJECTIVES: We aimed to compare the efficacy of ruxolitinib, anakinra, and etoposide-based therapies for the management of HLH in adult patients...
2024: Therapeutic Advances in Hematology
keyword
keyword
1828
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.